GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » Cash Flow from Operations

Remedent (Remedent) Cash Flow from Operations : $0.25 Mil (TTM As of Dec. 2020)


View and export this data going back to 2000. Start your Free Trial

What is Remedent Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2020, Remedent's Net Income From Continuing Operations was $0.10 Mil. Its Depreciation, Depletion and Amortization was $0.01 Mil. Its Change In Working Capital was $0.01 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $-0.05 Mil. In all, Remedent's Cash Flow from Operations for the three months ended in Dec. 2020 was $0.07 Mil.


Remedent Cash Flow from Operations Historical Data

The historical data trend for Remedent's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remedent Cash Flow from Operations Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.20 1.67 0.02 0.57 0.10

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.07 0.02 0.10 0.07

Remedent Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Remedent's Cash Flow from Operations for the fiscal year that ended in Mar. 2020 is calculated as:

Remedent's Cash Flow from Operations for the quarter that ended in Dec. 2020 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remedent  (OTCPK:REMI) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Remedent's net income from continuing operations for the three months ended in Dec. 2020 was $0.10 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Remedent's depreciation, depletion and amortization for the three months ended in Dec. 2020 was $0.01 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Remedent's change in working capital for the three months ended in Dec. 2020 was $0.01 Mil. It means Remedent's working capital increased by $0.01 Mil from Sep. 2020 to Dec. 2020 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Remedent's cash flow from deferred tax for the three months ended in Dec. 2020 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Remedent's cash from discontinued operating Activities for the three months ended in Dec. 2020 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Remedent's asset impairment charge for the three months ended in Dec. 2020 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Remedent's stock based compensation for the three months ended in Dec. 2020 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Remedent's cash flow from others for the three months ended in Dec. 2020 was $-0.05 Mil.


Remedent Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Remedent's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Remedent (Remedent) Business Description

Traded in Other Exchanges
N/A
Address
Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc 10 percent owner 234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross director, officer: CFO; Secretary XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van director C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List other: Former Officer and Director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington officer: Sr VP & Head of US Marketing C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese director, officer: Chairman of the Board XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman officer: VP Worldwide Sales/Operations 702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha 10 percent owner C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind 05-26-2011